Safety of Ovaleap® (Follitropin alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies. A Multi-National, Comparative, Prospective, Non-Interventional, Observational Cohort Study (SOFIA)

First published: 19/01/2017 Last updated: 07/07/2025





### Administrative details

#### **EU PAS number**

**EUPAS17328** 

Study ID

41256

**DARWIN EU® study** 

No

**Study countries** 

Belgium		
France		
Germany		
Italy		
Spain		
United Kingdom		

#### Study description

The EMA has requested post authorization safety data to examine the risk of Ovarian Hyperstimulation Syndrome (OHSS), a potentially serious adverse effect under treatment with recombinant human follicle stimulating hormone (r-hFSH), in Ovaleap® compared to Gonal-f®.

An observational Post-Authorisation Safety Study (PASS) will therefore be performed. This is a multi-national, comparative, prospective, non interventional, observational cohort study.

The study population will comprise infertile women, who have not previously received treatment with any FSH or any product containing FSH activity, and who are undergoing Assisted Reproductive Technology (ART) and are administered Ovaleap or Gonal-f for ovarian stimulation according to site standard of care.

#### **Study status**

Finalised

Research institutions and networks

**Institutions** 

# Multiple centres: 56 centres are involved in the study

## Contact details

### **Study institution contact**

Marina Todorova safety.global@theramex.com

Study contact

safety.global@theramex.com

#### **Primary lead investigator**

George Haralabopoulos

**Primary lead investigator** 

# Study timelines

### Date when funding contract was signed

Planned: 31/10/2016

Actual: 21/12/2016

#### Study start date

Planned: 31/01/2017

Actual: 27/01/2017

Date of interim report, if expected

Planned: 31/07/2020

Actual: 31/07/2020

#### **Date of final study report**

Planned: 30/09/2020

Actual: 30/12/2020

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

Theramex HQ UK Ltd

# Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

# Methodological aspects

Study type

Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

#### **Study type:**

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness Safety study (incl. comparative)

#### **Data collection methods:**

Combined primary data collection and secondary use of data

### Main study objective:

The primary objective of the study is to assess the safety of Ovaleap compared to Gonal-f in one treatment cycle with respect to the incidence rates of OHSS in infertile women undergoing super-ovulation for assisted reproductive technologies (ART).

# Study Design

### Non-interventional study design

Cohort

# Study drug and medical condition

#### Name of medicine

# Study drug International non-proprietary name (INN) or common name FOLLITROPIN ALFA

#### **Anatomical Therapeutic Chemical (ATC) code**

(G03GA05) follitropin alfa follitropin alfa

#### Medical condition to be studied

Infertility

# Population studied

#### Short description of the study population

The study population will comprise infertile women, who have not previously received treatment with any FSH (ie, r-hFSH, u-hFSH) and/or hMG, who are undergoing ART and are administered Ovaleap or Gonal-f for ovarian stimulation.

#### Inclusion Criteria

Patients may be included in the study only if they meet all of the following criteria:

- a. Signed and dated written informed consent
- b. Infertile female patients naïve to any FSH (r-hFSH, u-hFSH) or hMG treatment undergoing superovulation for ART and about to start first treatment with Ovaleap or Gonal-f for ovarian stimulation
- c. A negative pregnancy test prior to treatment

**Exclusion Criteria** 

Patients will be excluded from participating in this study if they meet any of the following criteria:

- a. Primary ovarian failure
- b. Ovarian enlargement or cyst not due to polycystic ovarian syndrome
- c. Neoplasm (e.g. tumors of the ovary, breast, uterus, hypothalamus, or pituitary gland)
- d. Prior history of OHSS.
- e. Prior history of any r-hFSH use (eg, Puregon, Ovaleap, Bemfola, Elonva and/or Gonal-f), u-hFSH (eg, Bravelle and/or Fostimon) and/or hMG (eg, Menopur)
- f. Known allergy or hypersensitivity to recombinant FSH preparations or one of their excipients
- g. Gynecologic bleeding (haemorrhages) of unknown aetiology
- h. Any other contra-indications to receive r-hFSH

#### **Age groups**

Adults (18 to < 46 years)

#### **Estimated number of subjects**

820

# Study design details

#### **Outcomes**

Primary endpoint: OHSS,

- Severity grade of OHSS (WHO Scientific Group classification 1973)
- Adverse events/adverse drug reactions

#### Data analysis plan

Descriptive summary statistics (including number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables, and number and percentage of patients per category for categorical variables) will be provided for all variables.

The primary objective of the study is to compare the incidence rate of OHSS in both Ovaleap and Gonal-f groups. The incidence rate of OHSS in both groups (along with the 95% CI) and the difference in OHSS incidence (Ovaleap - Gonal-f) along with the two-sided 95% CI will be calculated.

In addition, a logistic regression model will be constructed to estimate the effect of age, country, and other baseline variables on the OHSS rate.

## Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

### Data sources (types)

Other

### Data sources (types), other

Prospective patient-based data collection, Other physicians might be contacted to retrieve additional follow up and safety information, medical records

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**

No